Valneva SE
PAR:VLA

Watchlist Manager
Valneva SE Logo
Valneva SE
PAR:VLA
Watchlist
Price: 3.73 EUR -2.56% Market Closed
Market Cap: 641.4m EUR

Valneva SE
Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Valneva SE
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Valneva SE
PAR:VLA
Common Stock
€25.5m
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
9%
Nanobiotix SA
PAR:NANO
Common Stock
€1.4m
CAGR 3-Years
11%
CAGR 5-Years
16%
CAGR 10-Years
13%
G
Genfit SA
PAR:GNFT
Common Stock
€12.5m
CAGR 3-Years
0%
CAGR 5-Years
5%
CAGR 10-Years
8%
Inventiva SA
PAR:IVA
Common Stock
€957k
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cellectis SA
PAR:ALCLS
Common Stock
$5.9m
CAGR 3-Years
26%
CAGR 5-Years
16%
CAGR 10-Years
14%
DBV Technologies SA
PAR:DBV
Common Stock
$15.4m
CAGR 3-Years
13%
CAGR 5-Years
22%
CAGR 10-Years
23%
No Stocks Found

Valneva SE
Glance View

Market Cap
605.7m EUR
Industry
Biotechnology

Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

VLA Intrinsic Value
10.28 EUR
Undervaluation 64%
Intrinsic Value
Price

See Also

What is Valneva SE's Common Stock?
Common Stock
25.5m EUR

Based on the financial report for Jun 30, 2025, Valneva SE's Common Stock amounts to 25.5m EUR.

What is Valneva SE's Common Stock growth rate?
Common Stock CAGR 10Y
9%

Over the last year, the Common Stock growth was 22%. The average annual Common Stock growth rates for Valneva SE have been 13% over the past three years , 13% over the past five years , and 9% over the past ten years .

Back to Top